KOD

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California, dedicated to developing innovative therapies targeting retinal diseases. Leveraging proprietary technologies, Kodiak aims to fulfill significant unmet medical needs in ophthalmology, showcased by its robust and diverse pipeline of product candidates. With a strategic emphasis on transformative treatments, the company is well-positioned to make a substantial impact on the global healthcare landscape while delivering value to its stakeholders in the dynamic eye care market.